Among the companies with shares expected to actively trade in
Monday's session are Bristol-Myers Squibb Co. (BMY), Pfizer Inc.
(PFE) and Momenta Pharmaceuticals Inc. (MNTA).
Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) said the
U.S. Food and Drug Administration has requested more information on
their anti-clotting drug Eliquis. The request pushes back the
potential for U.S. sales of the drug, which is already approved in
Europe. Shares of the smaller Bristol-Myers dropped 4.6% to $33.75
in premarket trading while Pfizer shares were last trading down
2.3% to $22.21.
Teva Pharmaceutical Industries Ltd. (TEVA) said a U.S. district
court validated its patents for the multiple-sclerosis drug
Copaxone and found purported generic versions by Mylan Inc. (MYL)
and Momenta Pharmaceuticals Inc. (MNTA) infringe those patents. The
news lifted Teva shares 7% to $40.70 premarket, while sending
Momenta shares plunging 21% to $13.50 premarket. Shares of the
larger Mylan were trading slightly lower at $21.10.
Ventrus Biosciences Inc.'s (VTUS) hemorrhoidal disease treatment
iferanserin failed to meet primary endpoints in a Phase 3 trial.
Shares of the development-stage pharmaceutical plunged plunged 57%
to $5.21 premarket as it said it has no immediate plans to continue
the drug's development.
Lexicon Pharmaceuticals Inc. (LXRX) said a study showed the
combined use of its LX4211 with the established diabetes therapy
metformin reduced the amount of glucose in patients with poorly
controlled type 2 diabetes. Shares jumped 14% to $2.17
premarket.
Watchlist:
Moody's Investors Service raised its ratings on Dillard's Inc.
(DDS) one notch closer to investment grade, citing the
department-store operator's continued strong operating
performance.
Restaurant operator J. Alexander's Corp. (JAX) agreed to be
acquired by a unit of insurer Fidelity National Financial Inc.
(FNF) in a cash-and-stock deal that values it at roughly $72
million.
Kirby Corp. (KEX) lowered its second-quarter and full-year
earnings estimates, noting softness in its land-based diesel engine
services business.
Analysts at Goldman Sachs upgraded SanDisk Corp. (SNDK) to buy
from neutral, saying current oversupply conditions should ease by
the fourth quarter, helping the data-storage company to see better
margins.
St. Jude said late Friday that it has identified a single Durata
defibrillator lead that was damaged due to an external abrasion,
but said the lead did not have the critical flaw of an earlier
version of the device that St. Jude no longer sells.
-Write to Mia Lamar at mia.lamar@dowjones.com